Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo.
The confirmatory trial evaluated teprotumumab for the treatment of active thyroid eye disease.
The primary endpoint of the study was met, with 82.9% of 41 teprotumumab-treated patients achieving a 2 mm or more reduction of proptosis compared with 9.5% of 42 placebo patients, a statically significant difference (P < .001), according to a press release from Horizon Pharma.
All secondary endpoints were met in the study. A greater